# Atomoxetine Hydrochloride Versus Placebo in Taiwanese Children and Adolescents With ADHD

> **NCT00485459** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 106 (actual)

## Conditions studied

- Attention Deficit Hyperactivity Disorder

## Interventions

- **DRUG:** Atomoxetine Hydrochloride
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00485459
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02
- **Primary completion:** —
- **Final completion:** 2004-11
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2007-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00485459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00485459, "Atomoxetine Hydrochloride Versus Placebo in Taiwanese Children and Adolescents With ADHD". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00485459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*